Novartis leadership reshuffle brings Biogen Idec talent to Sandoz
This article was originally published in Scrip
Jeff George, head of Novartis's generics business Sandoz since December 2008, is to take over the leadership of its eye care business Alcon. He will replace the retiring Kevin Buehler, who has been with the company for 30 years. Mr George's replacement at Sandoz is Biogen Idec's senior vice president, US commercial operations, Richard Francis.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.